Lucentis (ranibizumab ophthalmic) Disease Interactions
There are 2 disease interactions with Lucentis (ranibizumab ophthalmic):
Intravitreal Injections (Includes Lucentis) ↔ Ocular Infections
Severe Potential Hazard, High plausibility
Applies to: Ocular Infection, Uveitis, Orbital Infection, Infectious Endophthalmitis, Infectious Optic Neuritis
Intravitreal administration, including those with aflibercept, pegaptanib, and ranibizumab is contraindicated in patients with active intraocular inflammation or ocular/periocular infections, since endophthalmitis can occur following the use of these injections. Patients should be advised to seek immediate medical attention from an ophthalmologist if the eye becomes red, photosensitive or painful, or if there is a change in vision in the days following the injection.
Ranibizumab Intravitreal Injection (Includes Lucentis) ↔ Increased Intraocular Pressure
Moderate Potential Hazard, Moderate plausibility
Applies to: Glaucoma/Intraocular Hypertension
Increases in intraocular pressure have been reported both pre- injection and post- injection (at 60 minutes) while being treated with ranibizumab. Intraocular pressure should be monitored prior and following intravitreal injection with ranibizumab and managed appropriately.
Lucentis (ranibizumab ophthalmic) drug Interactions
There is 1 drug interaction with Lucentis (ranibizumab ophthalmic)
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.